IRCT20151004024335N5 IRCT 2022-08-09 Kerman University of Medical Sciences Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI in Kernan in 2022 Evaluation and comparison of luteal phase support with vaginal and oral progesterone in IUI 2022-03-21 anticipated 288 Complete https://irct.ir/trial/61254 interventional Randomization: Randomized, Blinding: Not blinded, Placebo: Not used, Assignment: Parallel, Purpose: Treatment, Randomization description: Randomization was simple, individual, not blinded, using a random number table. 3 Infertility. Intervention 1: Intervention group: Intervention group: To start the IUI cycle, women are given ovulation-stimulating drugs in the form of letrozole or clomiphene tablets for five days from the third day of the menstrual cycle. Then, from the eighth day, the gonadotropin cycle starts with a dose of 150-175 units. On the eleventh day of the menstrual cycle, transvaginal ultrasound is performed to monitor the follicle. Depending on the size of the follicle, the drug is continued and the ultrasound is repeated until one or two follicles reach a size of 18 mm. If more than two follicles grow due to increased risk of multiple pregnancy or ovarian hyperstimulation, the cycle will be canceled. When the follicle size reaches 18 mm, 10,000 units of human chorionic gonadotropin (HCG) are used to stimulate ovulation. 36 hours after HCG injection, the partner's sperm is prepared by the infertility center laboratory and inseminated into the endometrial cavity with a sterile catheter by the infertility fellowship. Patients are then randomly divided into two groups. In the intervention group, which will consist of 144 women, oral diderogesterone tablets under the Dofaston brand are given as 10 mg three times a day and continue until the 11th week of pregnancy. Intervention 2: Control group: In the control group, after intrauterine insemination of sperm, a progesterone suppository called vaginal cyclogest 400 micrograms is administered twice a day. No - There is not a plan to make this available Justification or reason for not sharing IPD is The final result of the study will be published and there is no need to share individual participants' data